

Edgar Filing: PDL BIOPHARMA, INC. - Form SC 13G/A

PDL BIOPHARMA, INC.  
Form SC 13G/A  
April 09, 2013

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934  
(Amendment No.3)\*

NAME OF ISSUER: PDL BioPharma, Inc.

TITLE OF CLASS OF SECURITIES: Common Stock

CUSIP NUMBER: 69329Y104

DATE OF EVENT WHICH REQUIRES FILING OF THIS STATEMENT: March 31, 2013

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

- Rule 13d-1(b)
- Rule 13d-1(c)
- Rule 13d-1(d)

\*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be 'filed' for the purpose of Section 18 of the Securities Exchange Act of 1934 ('Act') or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP NUMBER: 69329Y104

- (1) Names of Reporting Persons The Bank of New York Mellon Corporation  
IRS Identification Nos. of Above Persons IRS No.13-2614959
- (2) Check the Appropriate Box if a Member of a Group (See Instructions)  
(a) ( ) (b) ( )
- (3) SEC use only
- (4) Citizenship or Place of Organization New York
- Number of Shares (5) Sole Voting Power 13,271,264  
Beneficially  
Owned by Each (6) Shared Voting Power 1,250  
Reporting Person  
With (7) Sole Dispositive Power 14,219,182  
(8) Shared Dispositive Power 2,500
- (9) Aggregate Amount Beneficially Owned  
by Each Reporting Person 14,342,705
- (10) Check if the Aggregated Amount in Row (9) Excludes Certain

Edgar Filing: PDL BIOPHARMA, INC. - Form SC 13G/A

Shares (see Instructions) ( )

- (11) Percent of Class Represented by Amount in Row (9) 10.25%
- (12) Type of Reporting Person (See Instructions) HC

CUSIP NUMBER: 69329Y104

(1) Names of Reporting Persons MBC Investments Corporation  
 IRS Identification Nos. of Above Persons IRS No.51-0301132

(2) Check the Appropriate Box if a Member of a Group (See Instructions)  
 (a) ( ) (b) ( )

(3) SEC use only

(4) Citizenship or Place of Organization Delaware

Number of Shares	(5)	Sole Voting Power	12,165,715
Beneficially			
Owned by Each	(6)	Shared Voting Power	0
Reporting Person			
With	(7)	Sole Dispositive Power	13,356,429
	(8)	Shared Dispositive Power	0

(9) Aggregate Amount Beneficially Owned  
 by Each Reporting Person 13,356,429

(10) Check if the Aggregated Amount in Row (9) Excludes Certain  
 Shares (see Instructions) ( )

- (11) Percent of Class Represented by Amount in Row (9) 9.54%
- (12) Type of Reporting Person (See Instructions) HC

CUSIP NUMBER: 69329Y104

(1) Names of Reporting Persons BNY Mellon Investment Management  
 (Jersey) Ltd.  
 IRS Identification Nos. of Above Persons IRS No.00-0000000

(2) Check the Appropriate Box if a Member of a Group (See Instructions)  
 (a) ( ) (b) ( )

(3) SEC use only

(4) Citizenship or Place of Organization London

Number of Shares	(5)	Sole Voting Power	11,126,248
Beneficially			
Owned by Each	(6)	Shared Voting Power	0
Reporting Person			
With	(7)	Sole Dispositive Power	12,262,690
	(8)	Shared Dispositive Power	0

(9) Aggregate Amount Beneficially Owned  
 by Each Reporting Person 12,262,690

Edgar Filing: PDL BIOPHARMA, INC. - Form SC 13G/A

- (10) Check if the Aggregated Amount in Row (9) Excludes Certain Shares (see Instructions) ( )
- (11) Percent of Class Represented by Amount in Row (9) 8.76%
- (12) Type of Reporting Person (See Instructions) HC

CUSIP NUMBER: 69329Y104

- (1) Names of Reporting Persons BNY Mellon Investment Management Europe) Ltd.  
 IRS Identification Nos. of Above Persons IRS No.00-0000000
- (2) Check the Appropriate Box if a Member of a Group (See Instructions)  
 (a) ( ) (b) ( )
- (3) SEC use only
- (4) Citizenship or Place of Organization London
- |   |                              |            |
|---|------------------------------|------------|
| Number of Shares Beneficially Owned by Each Reporting Person With | (5) Sole Voting Power        | 11,126,248 |
|   | (6) Shared Voting Power      | 0          |
|   | (7) Sole Dispositive Power   | 12,262,690 |
|   | (8) Shared Dispositive Power | 0          |
- (9) Aggregate Amount Beneficially Owned by Each Reporting Person 12,262,690
- (10) Check if the Aggregated Amount in Row (9) Excludes Certain Shares (see Instructions) ( )
- (11) Percent of Class Represented by Amount in Row (9) 8.76%
- (12) Type of Reporting Person (See Instructions) HC

CUSIP NUMBER: 69329Y104

- (1) Names of Reporting Persons BNY Mellon Investment Management Europe Holdings Ltd.  
 IRS Identification Nos. of Above Persons IRS No.00-0000000
- (2) Check the Appropriate Box if a Member of a Group (See Instructions)  
 (a) ( ) (b) ( )
- (3) SEC use only
- (4) Citizenship or Place of Organization London
- |   |                              |            |
|---|------------------------------|------------|
| Number of Shares Beneficially Owned by Each Reporting Person With | (5) Sole Voting Power        | 11,126,248 |
|   | (6) Shared Voting Power      | 0          |
|   | (7) Sole Dispositive Power   | 12,262,690 |
|   | (8) Shared Dispositive Power | 0          |
- (9) Aggregate Amount Beneficially Owned

Edgar Filing: PDL BIOPHARMA, INC. - Form SC 13G/A

by Each Reporting Person 12,262,690

- (10) Check if the Aggregated Amount in Row (9) Excludes Certain Shares (see Instructions) ( )
- (11) Percent of Class Represented by Amount in Row (9) 8.76%
- (12) Type of Reporting Person (See Instructions) HC

CUSIP NUMBER: 69329Y104

- (1) Names of Reporting Persons BNY Mellon International Asset Management Group Limited  
 IRS Identification Nos. of Above Persons IRS No.98-0464992
- (2) Check the Appropriate Box if a Member of a Group (See Instructions)  
 (a) ( ) (b) ( )
- (3) SEC use only
- (4) Citizenship or Place of Organization London
- Number of Shares (5) Sole Voting Power 11,126,248  
 Beneficially Owned by Each (6) Shared Voting Power 0  
 Reporting Person With (7) Sole Dispositive Power 12,262,690  
 (8) Shared Dispositive Power 0
- (9) Aggregate Amount Beneficially Owned by Each Reporting Person 12,262,690
- (10) Check if the Aggregated Amount in Row (9) Excludes Certain Shares (see Instructions) ( )
- (11) Percent of Class Represented by Amount in Row (9) 8.76%
- (12) Type of Reporting Person (See Instructions) HC

CUSIP NUMBER: 69329Y104

- (1) Names of Reporting Persons Newton Management Limited  
 IRS Identification Nos. of Above Persons IRS No.98-0196145
- (2) Check the Appropriate Box if a Member of a Group (See Instructions)  
 (a) ( ) (b) ( )
- (3) SEC use only
- (4) Citizenship or Place of Organization London
- Number of Shares (5) Sole Voting Power 11,126,248  
 Beneficially Owned by Each (6) Shared Voting Power 0  
 Reporting Person With (7) Sole Dispositive Power 12,262,690  
 (8) Shared Dispositive Power 0

Edgar Filing: PDL BIOPHARMA, INC. - Form SC 13G/A

(9) Aggregate Amount Beneficially Owned  
by Each Reporting Person 12,262,690

(10) Check if the Aggregated Amount in Row (9) Excludes Certain  
Shares (see Instructions) ( )

(11) Percent of Class Represented by Amount in Row (9) 8.76%

(12) Type of Reporting Person (See Instructions) HC

CUSIP NUMBER: 69329Y104

(1) Names of Reporting Persons Newton Investment Management Limited  
IRS Identification Nos. of Above Persons IRS No.98-0196228

(2) Check the Appropriate Box if a Member of a Group (See Instructions)  
(a) ( ) (b) ( )

(3) SEC use only

(4) Citizenship or Place of Organization London

Number of Shares (5) Sole Voting Power 11,007,548  
Beneficially  
Owned by Each (6) Shared Voting Power 0  
Reporting Person  
With (7) Sole Dispositive Power 11,997,995  
(8) Shared Dispositive Power 0

(9) Aggregate Amount Beneficially Owned  
by Each Reporting Person 11,997,995

(10) Check if the Aggregated Amount in Row (9) Excludes Certain  
Shares (see Instructions) ( )

(11) Percent of Class Represented by Amount in Row (9) 8.57%

(12) Type of Reporting Person (See Instructions) IA

SCHEDULE 13G

Item 1(a) Name of Issuer: PDL BioPharma, Inc.

Item 1(b) Address of Issuer's Principal Executive Office:  
932 Southwood Boulevard  
Incline Village, Nevada 89451  
United States

Item 2(a) Name of Person Filing: The Bank of New York Mellon Corporation  
and any other reporting person(s)  
identified on the second part of the  
cover page(s) and Exhibit I

Item 2(b) Address of Principal Business Office, or if None, Residence:  
C/O The Bank of New York Mellon Corporation  
One Wall Street, 31st Floor  
New York, New York 10286

Edgar Filing: PDL BIOPHARMA, INC. - Form SC 13G/A

(for all reporting persons)

Item 2(c) Citizenship: See cover page and Exhibit I

Item 2(d) Title of Class of Securities: Common Stock

CUSIP Number 69329Y104

Item 3 See Item 12 of cover page(s) ("Type of Reporting Person ") for each reporting person.

Symbol Category

- BD = Broker or Dealer registered under Section 15 of the Securities Exchange Act of 1934
- BK = Bank as defined in Section 3(a)(6) of the Securities Exchange Act of 1934
- IV = Investment Company registered under Section 8 of the Investment Company Act of 1940
- IA = Investment Advisor registered under Section 203 of the Investment Advisors Act of 1940
- EP = Employee Benefit Plan, Pension Fund which is subject to the provisions of the Employee Retirement Income Security Act of 1974 or Endowment Fund; see Section 240.13 - d(1)(b)(1)(ii)(F)
- HC = Parent Holding Company, in accordance with Section 240.13-d(1)(b)(1)(ii)(G)

Item 4 Ownership: See Item 5 through 9 and 11 of cover page(s) as to each reporting person.

The amount beneficially owned includes, where appropriate, securities not outstanding which are subject to options, warrants, rights or conversion privileges that are exercisable within 60 days. The securities reported herein as beneficially owned may exclude securities of the issuer with respect to which voting and/or dispositive power is exercised by subsidiaries of The Bank of New York Mellon Corporation, or departments or units thereof, independently from the exercise of those powers over the securities reported herein. See SEC Release No. 34-39538 (January 12, 1998). The filing of this Schedule 13G shall not be construed as an admission that The Bank of New York Mellon Corporation, or its direct or indirect subsidiaries, including The Bank of New York Mellon and BNY Mellon, National Association, are for the purposes of Section 13(d) or 13(g) of the Act, the beneficial owners of any securities covered by this Schedule 13G.

The following information applies if checked: ( ) The Bank of New York Mellon and/or ( ) The Bank of New York Mellon Trust Company, National Association is/are the trustee of the issuer's employee benefit plan (the Plan), which is subject to ERISA. The securities reported include all shares held of record by such reporting person(s) as trustee of the Plan which have not been allocated to the individual accounts of employee participants in the Plan. The reporting person, however, disclaims beneficial ownership of all shares that have been allocated to the individual accounts of employee participants in the Plan for which directions have been received and followed.

Item 5 Ownership of Five Percent or Less of a Class:

Edgar Filing: PDL BIOPHARMA, INC. - Form SC 13G/A

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ( )

Item 6 Ownership of More than Five Percent on Behalf of Another Person:

All of the securities are beneficially owned by The Bank of New York Mellon Corporation and its direct or indirect subsidiaries in their various fiduciary capacities. As a result, another entity in every instance is entitled to dividends or proceeds of sale. The number of individual accounts holding an interest of 5% or more is ( )

Item 7 Identification and Classification of the Subsidiary Which Acquired the Security Being Reported by the Parent Holding Company:  
See Exhibit I.

Item 8 Identification and Classification of Members of the Group: N/A

Item 9 Notice of Dissolution of Group: N/A

Item 10 Certification:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of and do not have the effect of changing or influencing the control of the issuer of such securities and were not acquired and are not held in connection with or as a participant in any transaction having such purpose or effect.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. This filing is signed by The Bank of New York Mellon Corporation on behalf of all reporting entities pursuant to Rule 13d-1(k)(1) promulgated under the Securities and Exchange Act of 1934, as amended.

Date: April 09, 2013

THE BANK OF NEW YORK MELLON CORPORATION

By: /s/ NICHOLAS R. DARROW

-----  
Nicholas R. Darrow  
Senior Vice President  
Attorney-In-Fact for  
The Bank of New York Mellon Corporation

EXHIBIT I

The shares reported on the attached Schedule 13G are beneficially owned by the following direct or indirect subsidiaries of The Bank of New York Mellon Corporation, as marked (X):

- (A) The Item 3 classification of each of the subsidiaries listed below is "Item 3(b) Bank as defined in Section 3(a)(6) of the Act" (15 U.S.C. 78c) or "Item 3(j)A non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J)"

## Edgar Filing: PDL BIOPHARMA, INC. - Form SC 13G/A

- (X) The Bank of New York Mellon
  - ( ) The Bank of New York Mellon Trust Company, National Association
  - (X) BNY Mellon, National Association
  - ( ) BNY Mellon Trust of Delaware
- (B) The Item 3 classification of each of the subsidiaries listed below is "Item 3(e) An investment adviser in accordance with Section 240.13d-1(b)(1)(ii)(E)" or "Item 3(j) A non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J)"
- ( ) BNY Mellon ARX Investimentos Ltda (parent holding company of BNY Mellon ARX Ativos Financeiros Ltda)
  - ( ) The Boston Company Asset Management LLC
  - (X) The Dreyfus Corporation (parent holding company of MBSC Securities Corporation)
  - ( ) Insight Investment Management (Global) Limited
  - ( ) Lockwood Advisors, Inc.
  - (X) Mellon Capital Management Corporation
  - (X) Newton Capital Management Limited
  - (X) Newton Investment Management Limited
  - ( ) Standish Mellon Asset Management Company LLC
  - ( ) Urdang Securities Management, Inc.
  - ( ) Urdang Capital Management, Inc.
  - ( ) Walter Scott & Partners Limited
- (C) The Item 3 classification of each of the subsidiaries listed below is "Item 3(a) Broker or dealer registered under Section 15 of the Act" (15 U.S.C. 78c) or "Item 3(j) A non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J)"
- ( ) MBSC Securities Corporation
  - (X) Pershing LLC
- (D) The Item 3 classification of each of the subsidiaries listed below is "Item 3(g) a parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G)"
- (X) The Bank of New York Mellon Corporation
  - ( ) B.N.Y. Holdings (Delaware) Corporation (parent holding company of BNY Mellon Trust of Delaware)
  - ( ) Insight Investment Management Limited (parent holding company of Insight Investment Management (Global) Limited)
  - ( ) MAM (MA) Holding Trust (parent holding company of Standish Mellon Asset Management Company LLC; The Boston Company Asset Management LLC)
  - (X) MBC Investments Corporation (parent holding company of Mellon Capital Management Corporation; BNY Mellon Investment Management (Jersey) Ltd. )
  - (X) BNY Mellon Investment Management (Jersey) Ltd. (parent holding company of BNY Mellon Investment Management (Europe) Ltd.)
  - (X) BNY Mellon Investment Management (Europe) Ltd. (parent holding company of BNY Mellon Investment Management Europe Holdings Ltd.)
  - (X) BNY Mellon Investment Management Europe Holdings Ltd. (parent holding company of BNY Mellon International Asset Management Group Limited; Mellon JV Limited)
  - (X) BNY Mellon International Asset Management Group Limited (parent holding company of Newton Management Limited; BNY Mellon International Asset Management (Holdings) Limited; Insight Investment Management Limited)
  - ( ) BNY Mellon Asset Management International Holdings Limited (parent holding company of BNY Mellon Asset Management Japan Limited)
  - ( ) Mellon Overseas Investment Corporation (parent holding company to



## Edgar Filing: PDL BIOPHARMA, INC. - Form SC 13G/A

- BNY Mellon Servicos Financeiros Distribuidora de Titulos e Valores Mobiliarios S.A. and (indirect) BNY Mellon Gestao de Patrimonio Ltda)
- (X) Newton Management Limited (parent holding company of Newton Capital Management Limited; Newton Investment Management Limited)
  - (X) Pershing Group LLC (parent holding company of Lockwood Advisors, Inc. and Pershing LLC)
  - ( ) The Bank of New York Mellon SA/NV (parent holding company of BNY Mellon Service Kapitalanlage-Gesellschaft mbH)
  - ( ) Mellon JV Limited (parent holding company of BNY Mellon Investment Holdings (Germany) Limited)
  - ( ) BNY Mellon Investment Holdings (Germany) Limited (parent holding company of Meriten Investment Management GmbH)
  - ( ) BNY Mellon International Asset Management (Holdings) Limited (parent holding company of BNY Mellon International Asset Management (Holdings) No. 1 Limited)
  - ( ) BNY Mellon International Asset Management (Holdings) No. 1 Limited (parent holding company of Walter Scott & Partners Limited)

NOTE: ALL OF THE LEGAL ENTITIES LISTED UNDER (A), (B), (C) AND (D) ABOVE ARE DIRECT OR INDIRECT SUBSIDIARIES OF THE BANK OF NEW YORK MELLON CORPORATION. BENEFICIAL OWNERSHIP OF MORE THAN FIVE PERCENT OF THE CLASS BY ANY ONE OF THE SUBSIDIARIES OR INTERMEDIATE PARENT HOLDING COMPANIES LISTED ABOVE IS REPORTED ON A JOINT REPORTING PERSON PAGE FOR THAT SUBSIDIARY ON THE ATTACHED SCHEDULE 13G AND IS INCORPORATED IN THE TOTAL PERCENT OF CLASS REPORTED ON THE BANK OF NEW YORK MELLON CORPORATION'S REPORTING PERSON PAGE. (DO NOT ADD THE SHARES OR PERCENT OF CLASS REPORTED ON EACH JOINT REPORTING PERSON PAGE ON THE ATTACHED SCHEDULE 13G TO DETERMINE THE TOTAL PERCENT OF CLASS FOR THE BANK OF NEW YORK MELLON CORPORATION).

### POWER OF ATTORNEY

KNOW ALL PERSONS BY THESE PRESENTS that each of the undersigned (each a "Company") does hereby make, constitute and appoint each of Kenneth J. Bradle, Sri Gupta, John E. Thomas, Jr., Nicholas R. Darrow, (and any other employee of The Bank of New York Mellon Corporation, or one of its affiliates, designated in writing by one of the attorneys-in-fact), acting individually, its true and lawful attorney, to execute and deliver in its name and on its behalf, whether the Company is acting individually or as representative of others, any and all filings, be they written or oral, required to be made by the Company with respect to securities which may be deemed to be beneficially owned by the Company or under the Company's investment discretion under:

\*the Securities Exchange Act of 1934, as amended (the "Exchange Act"), including those filings required to be submitted on Form 13F, Schedule 13G and Form SH, and

\*the laws of any jurisdiction other than the United States of America, including those filings made to disclose securities holdings as required to be submitted to regulatory agencies, exchanges and/or issuers,

giving and granting unto each said attorney-in-fact power and authority to correspond with issuers, regulatory authorities, and other entities as is required in support of the filings referenced above, and to act in the premises as fully and to all intents and purposes as the Company might or could do to comply with the applicable regulations if personally present by one of its authorized signatories (including, but not limited to, instructing local counsel on a Company's behalf), hereby ratifying and confirming all that

Edgar Filing: PDL BIOPHARMA, INC. - Form SC 13G/A

said attorney-in-fact shall lawfully do or cause to be done by virtue hereof.

THIS POWER OF ATTORNEY shall remain in full force and effect until either revoked in writing by the Company or until such time as the person or persons to whom power of attorney has been hereby granted cease(s) to be an employee of The Bank of New York Mellon Corporation or one of its affiliates.

This Power of Attorney may be executed in any number of counterparts all of which taken together shall constitute one and the same instrument.

IN WITNESS WHEREOF, the undersigned hereby execute this Agreement effective as of the date set forth below.

-----  
Banks/Bank Holding Companies

THE BANK OF NEW YORK MELLON CORPORATION

BNY MELLON, NATIONAL ASSOCIATION

By: /S/ RONALD P. O'HANLEY  
-----

By: /S/ GERALD L. HASSELL  
-----

Ronald P. O'Hanley  
Vice Chairman

Gerald L. Hassell  
President

Date: October 12, 2009

Date: October 12, 2009

THE BANK OF NEW YORK MELLON

THE BANK OF NEW YORK MELLON

By: /S/ GERALD L. HASSELL  
-----

By: /S/ DONALD R. MONKS  
-----

Gerald L. Hassell  
President

Donald R. Monks  
Vice Chairman

Date: October 12, 2009

Date: October 12, 2009

THE BANK OF NEW YORK MELLON TRUST COMPANY, NATIONAL ASSOCIATION

THE BANK OF NEW YORK MELLON TRUST COMPANY, NATIONAL ASSOCIATION

By: /S/ KAREN A. BAYZ  
-----

By: /S/ JOHN A. PARK  
-----

Karen A. Bayz  
Managing Director and  
Chief Financial Officer

John A. Park  
Executive Vice President

Date: October 13, 2009

Date: October 9, 2009

BNY MELLON TRUST OF DELAWARE

BNY MELLON TRUST OF DELAWARE

By: /S/ DAVID B. KUTCH  
-----

By: /S/ DONALD R. MONKS  
-----

David B. Kutch  
Chairman and  
Chief Executive Officer

Donald R. Monks  
Senior Executive Vice President

Date: October 12, 2009

Date: October 12, 2009

-----  
Investment Advisers and/or Broker-Dealers

PERSHING LLC

Edgar Filing: PDL BIOPHARMA, INC. - Form SC 13G/A

By: /S/ GARY JOHNSON

-----  
Gary Johnson  
Managing Director

Date: December 10, 2010

BNY MELLON ARX INVESTIMENTOS LTDA

By: /S/ JOSE CARLOS LOPES XAVIER  
DE OLIVEIRA

-----  
Jose Carlos Lopes Xavier De Oliveira  
Chief Executive Officer

Date: January 4, 2010

BNY MELLON ARX INVESTIMENTOS LTDA

By: /S/ MARCELO PERIERA DA SILVA

-----  
Marcelo Periera da Silva  
Chief Financial Officer

Date: January 4, 2010

BNY MELLON SERVICOS FINANCEIROS  
DISTRIBUIDORA DE TITULOS E VALORES  
MOBILIARIOS S.A

By: /S/ JOSE CARLOS LOPES XAVIER  
DE OLIVEIRA

-----  
Jose Carlos Lopes Xavier De Oliveira  
Chief Executive Officer

Date: January 4, 2010

BNY MELLON SERVICOS FINANCEIROS  
DISTRIBUIDORA DE TITULOS E VALORES  
MOBILIARIOS S.A

By: /S/ MARCELO PERIERA DA SILVA

-----  
Marcelo Periera da Silva  
Chief Financial Officer

Date: January 4, 2010

BNY MELLON ARX ATIVOS FINANCEIROS  
LTDA

By: /S/ JOSE CARLOS LOPES XAVIER  
DE OLIVEIRA

-----  
Jose Carlos Lopes Xavier De Oliveira  
Chief Executive Officer

Date: January 4, 2010

BNY MELLON ARX ATIVOS FINANCEIROS  
LTDA

By: /S/ MARCELO PERIERA DA SILVA

-----  
Marcelo Periera da Silva  
Chief Financial Officer

Date: January 4, 2010

BNY MELLON GESTAO DE PATRIMONIO LTDA

By: /S/ JOSE CARLOS LOPES XAVIER  
DE OLIVEIRA

-----  
Jose Carlos Lopes Xavier De Oliveira  
Chief Executive Officer

Date: January 4, 2010

BNY MELLON GESTAO DE PATRIMONIO LTDA

By: /S/ MARCELO PERIERA DA SILVA

-----  
Marcelo Periera da Silva  
Chief Financial Officer

Date: January 4, 2010

THE BOSTON COMPANY ASSET MANAGEMENT  
LLC

By: /S/ DAVE CAMERON

-----  
Dave Cameron  
Chairman, President and  
Chief Executive Officer

Date: October 12, 2009

THE BOSTON COMPANY ASSET MANAGEMENT  
LLC

By: /S/ JOSEPH P. GENNACO

-----  
Joseph P. Gennaco  
Executive Vice President  
and Chief Operating Officer

Date: October 12, 2009

Edgar Filing: PDL BIOPHARMA, INC. - Form SC 13G/A

BNY MELLON ASSET MANAGEMENT JAPAN  
LIMITED

By: /S/ SHOGO YAMAGUCHI  
-----  
Shogo Yamaguchi  
President and  
Representative Director  
Date: December 29, 2009

BNY MELLON ASSET MANAGEMENT JAPAN  
LIMITED

By: /S/ DAVID JIANG  
-----  
David Jiang  
Chairman and  
Representative Director  
Date: December 29, 2009

THE DREYFUS CORPORATION

By: /S/ JAMES BITETTO  
-----  
James Bitetto  
Corporate Secretary  
Date: October 7, 2009

INSIGHT INVESTMENT (Global)  
MANAGEMENT LIMITED

By: /s/ CHARLES FARQUHARSON  
-----  
Charles Farquharson  
Chief Risk Officer  
Date: December 04, 2009

LOCKWOOD ADVISORS, INC.

By: /S/ DON MARCHESIELLO  
-----  
Don Marchesiello  
President  
Date: October 6, 2009

MELLON CAPITAL MANAGEMENT  
CORPORATION

By: /S/ CHARLES J. JACKLIN  
-----  
Charles J. Jacklin  
President and CEO  
Date: October 8, 2009

MBSC SECURITIES CORPORATION

By: /S/ KENNETH J. BRADLE  
-----  
Kenneth J. Bradle  
President  
Date: October 28, 2009

NEWTON INVESTMENT MANAGEMENT LIMITED

By: /S/ ANDREW DOWNS  
-----  
Andrew Downs  
Chief Operating Officer  
Date: November 6, 2009

NEWTON CAPITAL MANAGEMENT LIMITED

By: /S/ ANDREW DOWNS  
-----  
Andrew Downs  
Chief Operating Officer  
Date: November 6, 2009

STANDISH MELLON ASSET MANAGEMENT  
COMPANY LLC

By: /S/ DESMOND MAC INTYRE  
-----  
Desmond Mac Intyre  
President and CEO  
Date: November 19, 2009

PERSHING GROUP LLC

By: /S/ BRIAN T. SHEA  
-----  
Brian T. Shea  
Managing Director  
Date: October 9, 2009

URDANG CAPITAL MANAGEMENT, INC.

By: /S/ RICHARD J. FERST

URDANG CAPITAL MANAGEMENT, INC.

By: /S/ E. TODD BRIDDELL

Edgar Filing: PDL BIOPHARMA, INC. - Form SC 13G/A

-----  
Richard J. Ferst  
President and  
Chief Operating Officer  
Date: October 15, 2009

-----  
E. Todd Briddell  
Managing Director and  
Chief Investment Officer  
Date: October 15, 2009

URDANG SECURITIES MANAGEMENT, INC.

URDANG SECURITIES MANAGEMENT, INC.

By: /S/ E. TODD BRIDDELL  
-----  
E. Todd Briddell  
Managing Director  
and Chief Investment Officer  
Date: October 15, 2009

By: /S/ RICHARD J. FERST  
-----  
Richard J. Ferst  
President and  
Chief Operating Office  
Date: October 15, 2009

WALTER SCOTT & PARTNERS LIMITED

WALTER SCOTT & PARTNERS LIMITED

By: /S/ ANNA NICHOLL  
-----  
Anna Nicholl  
Chief Compliance Officer  
Date: October 8, 2009

By: /S/ CAROL-ANN FRASER  
-----  
Carol-Ann Fraser  
Compliance Officer  
Date: October 8, 2009

-----  
Parent Holding Companies/Control Persons

B.N.Y. HOLDINGS (DELAWARE) CORPORATION

By: /S/ JOHN A. PARK  
-----  
John A. Park  
Senior Vice President  
Date: October 9, 2009

BNY MELLON ASSET MANAGEMENT  
INTERNATIONAL HOLDINGS LIMITED

BNY MELLON ASSET MANAGEMENT  
INTERNATIONAL HOLDINGS LIMITED

By: /S/ GREG BRISK  
-----  
Greg Brisk  
Director  
Date: October 12, 2009

By: /S/ SHONA SPENCE  
-----  
Shona Spence  
Director  
Date: October 15, 2009

BNY MELLON INTERNATIONAL ASSET  
MANAGEMENT GROUP LIMITED

By: /S/ JEREMY N. BASSIL  
-----  
Jeremy N. Bassil  
Director  
Date: October 13, 2009

MAM (MA) HOLDING TRUST

MBC INVESTMENTS CORPORATION

By: /S/ RONALD P. O'HANLEY

By: /S/ GORDON MOTTER

Edgar Filing: PDL BIOPHARMA, INC. - Form SC 13G/A

-----  
Ronald P. O'Hanley  
President  
Date: October 9, 2009

-----  
Gordon Motter  
Chairman, President and CEO  
Date: October 9, 2009

NEWTON MANAGEMENT LIMITED

NEWTON MANAGEMENT LIMITED

By: /S/ HELENA MORRISSEY  
-----

By: /S/ ANDREW DOWNS  
-----

Helena Morrissey  
Director

Andrew Downs  
Director

Date: October 15, 2009

Date: November 6, 2009

MELLON OVERSEAS INVESTMENT  
CORPORATION

INSIGHT INVESTMENT MANAGEMENT  
LIMITED

By: /S/ JON LITTLE  
-----

By: /S/ CHARLES FARQUHARSON  
-----

Jon Little  
Chairman, President And  
Chief Executive Officer

Charles Farquharson  
Chief Risk Officer

Date: December 04, 2009

Date: December 04, 2009

BNY INTERNATIONAL FINANCING  
CORPORATION

THE BANK OF NEW YORK MELLON SA/NV

By: /S/ FRED RICCIARDI  
-----

By: /S/ JEAN-CHRISTOPHE MATHONET  
-----

Fred Ricciardi  
President

Jean-Christophe Mathonet  
Managing Director

Date: August 30, 2010

Date: October 4, 2010

BNY MELLON INVESTMENT HOLDINGS  
(GERMANY) LIMITED

MELLON JV LIMITED

By: /S/ MARTIN TILLERT  
-----

Martin Tillert  
Managing Director

Date: January 10, 2013

BNY MELLON INVESTMENT MANAGEMENT  
EUROPE HOLDINGS LIMITED

BNY MELLON INVESTMENT MANAGEMENT  
(EUROPE) LIMITED

By: /S/ GREG BRISK  
-----

By: /S/ GREG BRISK  
-----

Greg Brisk  
Director

Greg Brisk  
Director

Date: March 14, 2013

Date: March 14, 2013

BNY MELLON INVESTMENT MANAGEMENT  
(JERSEY) LIMITED

By: /S/ GREG BRISK  
-----

Greg Brisk

Edgar Filing: PDL BIOPHARMA, INC. - Form SC 13G/A

Director  
Date: March 14, 2013

BNY MELLON INTERNATIONAL ASSET  
MANAGEMENT (HOLDINGS) LIMITED  
By: /S/ GREG BRISK

-----  
Greg Brisk  
Director  
Date: April 5, 2013

BNY MELLON INTERNATIONAL ASSET  
MANAGEMENT (HOLDINGS) No. 1 LIMITED  
By: /S/ GREG BRISK

-----  
Greg Brisk  
Director  
Date: April 5, 2013

-----  
Fund Administrators

BNY MELLON SERVICE KAPITALANLAGE-  
GESELLSCHAFT mbH

By: /S/ CAROLINE SPECHT

-----  
Caroline Specht  
Managing Director, Head of  
Business Strategy and Legal  
Date: August 24, 2010

MERITEN INVESTMENT MANAGEMENT GmbH

By: /S/ WERNER TAIBER

-----  
Werner Taiber  
Chief Execution Officer  
Date: December 12, 2012

MERITEN INVESTMENT MANAGEMENT GmbH

By: /S/ DR. NORBERT BECKER

-----  
Dr. Norbert Becker  
Deputy Chief Execution Officer  
Date: December 12, 2012

JOINT FILING AGREEMENT

In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), the undersigned hereby agree to any and all joint filings required to be made on their behalf on Schedule 13G (including amendments thereto) under the Exchange Act, with respect to securities which may be deemed to be beneficially owned by them under the Exchange Act, and that this Agreement be included as an Exhibit to any such joint filing. This Agreement may be executed in any number of counterparts all of which taken together shall constitute one and the same instrument.

IN WITNESS WHEREOF, the undersigned hereby execute this Agreement effective as of the date set forth below.

-----  
Banks/Bank Holding Companies

THE BANK OF NEW YORK MELLON  
CORPORATION

By: /S/ RONALD P. O'HANLEY

BNY MELLON, NATIONAL ASSOCIATION

By: /S/ GERALD L. HASSELL

Edgar Filing: PDL BIOPHARMA, INC. - Form SC 13G/A

-----  
Ronald P. O'Hanley  
Vice Chairman  
Date: October 09, 2009

-----  
Gerald L. Hassell  
President  
Date: October 12, 2009

THE BANK OF NEW YORK MELLON

THE BANK OF NEW YORK MELLON

By: /S/ GERALD L. HASSELL  
-----  
Gerald L. Hassell  
President  
Date: October 12, 2009

By: /S/ DONALD R. MONKS  
-----  
Donald R. Monks  
Vice Chairman  
Date: October 12, 2009

THE BANK OF NEW YORK MELLON TRUST  
COMPANY, NATIONAL ASSOCIATION

THE BANK OF NEW YORK MELLON TRUST  
COMPANY, NATIONAL ASSOCIATION

By: /S/ KAREN A. BAYZ  
-----  
Karen A. Bayz  
Managing Director and  
Chief Financial Officer  
Date: October 13, 2009

By: /S/ JOHN A. PARK  
-----  
John A. Park  
Executive Vice President  
Date: October 9, 2009

BNY MELLON TRUST OF DELAWARE

BNY MELLON TRUST OF DELAWARE

By: /S/ DAVID B. KUTCH  
-----  
David B. Kutch  
Chairman and  
Chief Executive Officer  
Date: October 12, 2009

By: /S/ DONALD R. MONKS  
-----  
Donald R. Monks  
Senior Executive Vice President  
Date: October 12, 2009

-----  
Investment Advisers and/or Broker-Dealers

PERSHING LLC

By: /S/ GARY JOHNSON  
-----  
Gary Johnson  
Managing Director  
Date: December 10, 2010

BNY MELLON ARX INVESTIMENTOS LTDA

BNY MELLON ARX INVESTIMENTOS LTDA

By: /S/ JOSE CARLOS LOPES XAVIER  
DE OLIVEIRA  
-----  
Jose Carlos Lopes Xavier De Oliveira  
Chief Executive Officer  
Date: January 4, 2010

By: /S/ MARCELO PERIERA DA SILVA  
-----  
Marcelo Periera da Silva  
Chief Financial Officer  
Date: January 4, 2010

BNY MELLON SERVICOS FINANCEIROS  
DISTRIBUIDORA DE TITULOS E VALORES  
MOBILIARIOS S.A

BNY MELLON SERVICOS FINANCEIROS  
DISTRIBUIDORA DE TITULOS E VALORES  
MOBILIARIOS S.A



Edgar Filing: PDL BIOPHARMA, INC. - Form SC 13G/A

By: /S/ JOSE CARLOS LOPES XAVIER  
DE OLIVEIRA  
-----  
Jose Carlos Lopes Xavier De Oliveira  
Chief Executive Officer  
Date: January 4, 2010

By: /S/ MARCELO PERIERA DA SILVA  
-----  
Marcelo Periera da Silva  
Chief Financial Officer  
Date: January 4, 2010

BNY MELLON ARX ATIVOS FINANCEIROS  
LTDA

BNY MELLON ARX ATIVOS FINANCEIROS  
LTDA

By: /S/ JOSE CARLOS LOPES XAVIER  
DE OLIVEIRA  
-----  
Jose Carlos Lopes Xavier De Oliveira  
Chief Executive Officer  
Date: January 4, 2010

By: /S/ MARCELO PERIERA DA SILVA  
-----  
Marcelo Periera da Silva  
Chief Financial Officer  
Date: January 4, 2010

BNY MELLON GESTAO DE PATRIMONIO LTDA

BNY MELLON GESTAO DE PATRIMONIO LTDA

By: /S/ JOSE CARLOS LOPES XAVIER  
DE OLIVEIRA  
-----  
Jose Carlos Lopes Xavier De Oliveira  
Chief Executive Officer  
Date: January 4, 2010

By: /S/ MARCELO PERIERA DA SILVA  
-----  
Marcelo Periera da Silva  
Chief Financial Officer  
Date: January 4, 2010

THE BOSTON COMPANY ASSET MANAGEMENT  
LLC

THE BOSTON COMPANY ASSET MANAGEMENT  
LLC

By: /S/ DAVE CAMERON  
-----  
Dave Cameron  
Chairman, President and  
Chief Executive Officer  
Date: October 12, 2009

By: /S/ JOSEPH P. GENNACO  
-----  
Joseph P. Gennaco  
Executive Vice President  
and Chief Operating Officer  
Date: October 12, 2009

BNY MELLON ASSET MANAGEMENT JAPAN  
LIMITED

BNY MELLON ASSET MANAGEMENT JAPAN  
LIMITED

By: /S/ SHOGO YAMAGUCHI  
-----  
Shogo Yamaguchi  
President and  
Representative Director  
Date: December 29, 2009

By: /S/ DAVID JIANG  
-----  
David Jiang  
Chairman and  
Representative Director  
Date: December 29, 2009

THE DREYFUS CORPORATION

INSIGHT INVESTMENT (Global)  
MANAGEMENT LIMITED

By: /S/ JAMES BITETTO  
-----  
James Bitetto  
Corporate Secretary  
Date: October 7, 2009

By: /s/ CHARLES FARQUHARSON  
-----  
Charles Farquharson  
Chief Risk Officer  
Date: December 04, 2009

Edgar Filing: PDL BIOPHARMA, INC. - Form SC 13G/A

LOCKWOOD ADVISORS, INC.

By: /S/ DON MARCHESIELLO  
-----

Don Marchesiello  
President

Date: October 6, 2009

MELLON CAPITAL MANAGEMENT  
CORPORATION

By: /S/ CHARLES J. JACKLIN  
-----

Charles J. Jacklin  
President and CEO

Date: October 8, 2009

MBSC SECURITIES CORPORATION

By: /S/ KENNETH J. BRADLE  
-----

Kenneth J. Bradle  
President

Date: October 28, 2009

NEWTON INVESTMENT MANAGEMENT LIMITED

By: /S/ ANDREW DOWNS  
-----

Andrew Downs  
Chief Operating Officer

Date: November 6, 2009

NEWTON CAPITAL MANAGEMENT LIMITED

By: /S/ ANDREW DOWNS  
-----

Andrew Downs  
Chief Operating Officer

Date: November 6, 2009

STANDISH MELLON ASSET MANAGEMENT  
COMPANY LLC

By: /S/ DESMOND MAC INTYRE  
-----

Desmond Mac Intyre  
President and CEO

Date: November 19, 2009

PERSHING GROUP LLC

By: /S/ BRIAN T. SHEA  
-----

Brian T. Shea  
Managing Director

Date: October 9, 2009

URDANG CAPITAL MANAGEMENT, INC.

By: /S/ RICHARD J. FERST  
-----

Richard J. Ferst  
President and  
Chief Operating Officer

Date: October 15, 2009

URDANG CAPITAL MANAGEMENT, INC.

By: /S/ E. TODD BRIDDELL  
-----

E. Todd Briddell  
Managing Director and  
Chief Investment Officer

Date: October 15, 2009

URDANG SECURITIES MANAGEMENT, INC.

By: /S/ E. TODD BRIDDELL  
-----

E. Todd Briddell  
Managing Director  
and Chief Investment Officer

Date: October 15, 2009

URDANG SECURITIES MANAGEMENT, INC.

By: /S/ RICHARD J. FERST  
-----

Richard J. Ferst  
President and  
Chief Operating Office

Date: October 15, 2009

WALTER SCOTT & PARTNERS LIMITED

By: /S/ ANNA NICHOLL  
-----

WALTER SCOTT & PARTNERS LIMITED

By: /S/ CAROL-ANN FRASER  
-----

Edgar Filing: PDL BIOPHARMA, INC. - Form SC 13G/A

Anna Nicholl  
Chief Compliance Officer  
Date: October 8, 2009

Carol-Ann Fraser  
Compliance Officer  
Date: October 8, 2009

-----  
Parent Holding Companies/Control Persons

B.N.Y. HOLDINGS (DELAWARE) CORPORATION

By: /S/ JOHN A. PARK  
-----

John A. Park  
Senior Vice President  
Date: October 9, 2009

BNY MELLON ASSET MANAGEMENT  
INTERNATIONAL HOLDINGS LIMITED

By: /S/ GREG BRISK  
-----

Greg Brisk  
Director  
Date: October 12, 2009

BNY MELLON ASSET MANAGEMENT  
INTERNATIONAL HOLDINGS LIMITED

By: /S/ SHONA SPENCE  
-----

Shona Spence  
Director  
Date: October 15, 2009

BNY MELLON INTERNATIONAL ASSET  
MANAGEMENT GROUP LIMITED

By: /S/ JEREMY N. BASSIL  
-----

Jeremy N. Bassil  
Director  
Date: October 13, 2009

MAM (MA) HOLDING TRUST

By: /S/ RONALD P. O'HANLEY  
-----

Ronald P. O'Hanley  
President  
Date: October 9, 2009

MBC INVESTMENTS CORPORATION

By: /S/ GORDON MOTTER  
-----

Gordon Motter  
Chairman, President and CEO  
Date: October 9, 2009

NEWTON MANAGEMENT LIMITED

By: /S/ HELENA MORRISSEY  
-----

Helena Morrissey  
Director  
Date: October 15, 2009

NEWTON MANAGEMENT LIMITED

By: /S/ ANDREW DOWNS  
-----

Andrew Downs  
Director  
Date: November 6, 2009

MELLON OVERSEAS INVESTMENT  
CORPORATION

By: /S/ JON LITTLE  
-----

Jon Little

INSIGHT INVESTMENT MANAGEMENT  
LIMITED

By: /S/ CHARLES FARQUHARSON  
-----

Charles Farquharson

Edgar Filing: PDL BIOPHARMA, INC. - Form SC 13G/A

Chairman, President And  
Chief Executive Officer  
Date: December 04, 2009

Chief Risk Officer  
Date: December 04, 2009

BNY INTERNATIONAL FINANCING  
CORPORATION

THE BANK OF NEW YORK MELLON SA/NV

By: /S/ FRED RICCIARDI  
-----  
Fred Ricciardi  
President  
Date: August 30, 2010

By: /S/ JEAN-CHRISTOPHEMATHONET  
-----  
Jean-ChristopheMathonet  
Managing Director  
Date: October 4, 2010

BNY MELLON INVESTMENT HOLDINGS  
(GERMANY) LIMITED

MELLON JV LIMITED

By: /S/ MARTIN TILLERT  
-----  
Martin Tillert  
Managing Director  
Date: January 10, 2013

BNY MELLON INVESTMENT MANAGEMENT  
EUROPE HOLDINGS LIMITED

BNY MELLON INVESTMENT MANAGEMENT  
(EUROPE)LIMITED

By: /S/ GREG BRISK  
-----  
Greg Brisk  
Director  
Date: March 14, 2013

By: /S/ GREG BRISK  
-----  
Greg Brisk  
Director  
Date: March 14, 2013

BNY MELLON INVESTMENT MANAGEMENT  
(JERSEY)LIMITED

By: /S/ GREG BRISK  
-----  
Greg Brisk  
Director  
Date: March 14, 2013

BNY MELLON INTERNATIONAL ASSET  
MANAGEMENT (HOLDINGS) LIMITED

BNY MELLON INTERNATIONAL ASSET  
MANAGEMENT (HOLDINGS) No. 1 LIMITED

By: /S/ GREG BRISK  
-----  
Greg Brisk  
Director  
Date: April 5, 2013

By: /S/ GREG BRISK  
-----  
Greg Brisk  
Director  
Date: April 5, 2013

-----  
Fund Administrators

BNY MELLON SERVICE KAPITALANLAGE-  
GESELLSCHAFT mbH

Edgar Filing: PDL BIOPHARMA, INC. - Form SC 13G/A

By: /S/ CAROLINE SPECHT

-----

Caroline Specht  
Managing Director, Head of  
Business Strategy and Legal

Date: August 24, 2010

MERITEN INVESTMENT MANAGEMENT GmbH

MERITEN INVESTMENT MANAGEMENT GmbH

By: /S/ WERNER TAIBER

-----

Werner Taiber  
Chief Execution Officer

Date: December 12, 2012

By: /S/ DR. NORBERT BECKER

-----

Dr. Norbert Becker  
Deputy Chief Execution Officer

Date: December 12, 2012